Press Release: Vitality Biopharma Adopts New Name -- Malachite Innovations, Inc.
Press Release: Vitality Biopharma Adopts New Name -- Malachite Innovations, Inc.
Press Release: Vitality Biopharma Adopts New Name -- Malachite Innovations, Inc.
新聞稿：活力生物製藥公司採用新名稱--孔雀石創新公司
Vitality Biopharma Adopts New Name -- Malachite Innovations, Inc.
活力生物製藥公司採用新名稱--孔雀石創新公司。
New Corporate Name Reflects Company's Expanded Business Strategy, Corporate Restructuring, and Other Corporate Changes
新的公司名稱反映了公司的擴展業務戰略、公司重組和其他公司變化
CLEVELAND, Ohio, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. has changed its name to MALACHITE INNOVATIONS, INC. (OTC Mkts: MLCT) (pronounced "mal-a-kite") following a corporate restructuring intended to reflect the Company's expanded business strategy and corporate rebranding. The Company also announced other corporate changes in support of the Company's new strategic plan to create long-term sustainable value for its shareholders.
俄亥俄州克利夫蘭，2021年10月12日(環球通訊社)--Vitality Biophma，Inc.更名為孔雀石創新公司。(場外交易代碼：MLCT)(發音為“mal-a-kite”)，此前該公司進行了旨在反映公司擴大業務戰略和公司品牌重塑的公司重組。該公司還宣佈了其他公司變動，以支持公司為股東創造長期可持續價值的新戰略計劃。
Expanded Strategy
擴展戰略
Malachite has charted a dual, interconnected strategy to improve the health and wellness of people and our planet through the formation and operation of two new business units, Graphium Biosciences, Inc. and Daedalus Ecosciences, Inc.
孔雀石公司制定了一項雙重的、相互關聯的戰略，通過組建和運營兩個新的業務部門--石墨生物科學公司和Daedalus生態科學公司--來改善人類和我們這個星球的健康和福祉。
Graphium Biosciences, the newly-formed operating subsidiary dedicated to improving the health and wellness of people, will advance our broad portfolio of over 100 novel cannabinoid-glycoside compounds created using our proprietary enzymatic bioprocessing technologies to develop safe and effective novel treatments for chronic and debilitating conditions, with an initial focus on inflammatory bowel disease. Effective September 30, 2021, all of the Company's drug development operations will be conducted through Graphium Biosciences.
致力於改善人們的健康和健康的新成立的運營子公司Graphium Biosciences將推進我們利用我們的專有酶生物處理技術創造的100多種新型大麻苷化合物的廣泛產品組合，以開發針對慢性和衰弱疾病的安全有效的新療法，最初的重點是炎症性腸道疾病。從2021年9月30日起，該公司的所有藥物開發業務都將通過石墨生物科學公司進行。
Daedalus Ecosciences, the newly-formed operating subsidiary dedicated to improving the health and wellness of our planet, will seek to identify, invest in and reposition challenging environmental situations with a particular focus on technological innovations and eco-friendly solutions deployed in economically challenged communities. Effective September 30, 2021, all of the Company's environmental operations will be conducted through Daedalus Ecosciences.
Daedalus Ecosciences是一家新成立的運營子公司，致力於改善我們地球的健康和福祉，該公司將尋求識別、投資和重新定位具有挑戰性的環境狀況，特別關注在經濟困難社區部署的技術創新和生態友好型解決方案。從2021年9月30日起，該公司的所有環境業務都將通過Daedalus生態科學公司進行。
Malachite will serve as the publicly-traded holding company and oversee all strategic, financial and operational aspects of its wholly-owned subsidiaries, Graphium Biosciences and Daedalus Ecosciences.
孔雀石公司將作為上市控股公司，監督其全資子公司Graphium Biosciences和Daedalus Ecosciences的所有戰略、財務和運營方面。
Corporate Rebranding
企業品牌重塑
The Company's Board of Directors approved this name change in furtherance of our expanded strategy and to mark the rebirth of our Company as we transition to the value creation phase of our strategic plan after successfully executing our multi-year restructuring plan. Our new corporate name is derived from the malachite butterfly whose brilliant green wings and rebirth imagery symbolize powerful transformation, good fortune and future prosperity for those who innovate and change.
公司董事會批准了這一更名，以進一步推進我們的擴展戰略，並標誌着我們的公司在成功執行多年重組計劃後，過渡到我們戰略計劃的價值創造階段，從而標誌着我們公司的重生。我們的新公司名稱來源於孔雀石蝴蝶，它燦爛的綠色翅膀和重生的意象象徵着那些創新和變革的人強大的轉型、好運和未來的繁榮。
Effective October 12, 2021, FINRA has approved a change in the Company's trading symbol from VBIO to MLCT.
自2021年10月12日起，FINRA已批准將公司的交易代碼從VBIO改為MLCT。
In connection with this name change, Malachite has launched a new website to provide our shareholders and the financial community with detailed information about our corporate philosophy, innovations, team and investor resources. Our new website can be found at: www.malachiteinnovations.com.
與此次更名相關的是，孔雀石推出了一個新的網站，為我們的股東和金融界提供有關我們的公司理念、創新、團隊和投資者資源的詳細信息。我們的新網站是：www.malachiteInnovations.com。
Other Corporate Changes
其他公司變更
Effective September 30, 2021, our Board of Directors approved a change in the Company's fiscal year from the twelve months ending March 31 to the twelve months ending December 31. The Company will file a transition report on Form 10-K for the period ended December 31, 2021. The synchronization of the Company's fiscal year with the calendar year is intended to better align the Company's financial reporting schedule with other publicly-traded companies.
從2021年9月30日起，我們的董事會批准將公司的會計年度從截至3月31日的12個月改為截至12月31日的12個月。該公司將提交截至2021年12月31日的10-K表格過渡報告。本公司會計年度與歷年同步的目的是為了更好地使本公司的財務報告時間表與其他上市公司保持一致。
We also have moved our corporate headquarters from Los Angeles, California to Cleveland, Ohio where many of the Company's directors, officers and advisors are located. Additionally, our new corporate headquarters is intended to provide the Company with an attractive physical location to expand our organization in support of the anticipated growth of our Graphium Biosciences and Daedalus Ecosciences operations.
我們還將公司總部從加利福尼亞州的洛杉磯遷至俄亥俄州的克利夫蘭，公司的許多董事、高級管理人員和顧問都在那裏。此外，我們的新公司總部旨在為公司提供一個有吸引力的地理位置，以擴大我們的組織，以支持我們的石墨生物科學公司和Daedalus生態科學公司業務的預期增長。
About Malachite Innovations, Inc.
孔雀石創新公司簡介
Headquartered in Cleveland, Ohio, Malachite Innovations, Inc. is an innovative socially-conscious company dedicated to improving the health and wellness of people and our planet. Malachite deploys this dual, interconnected strategy through two wholly-owned operating subsidiaries. Graphium Biosciences, our operating subsidiary dedicated to improving the health and wellness of people, seeks to advance our broad portfolio of over 100 novel cannabinoid-glycoside compounds created using our proprietary enzymatic bioprocessing technologies to develop safe and effective novel treatments for chronic and debilitating conditions, with an initial focus on inflammatory bowel disease. Daedalus Ecosciences, our operating unit dedicated to improving the health and wellness of our planet, seeks to identify, invest in and reposition challenging environmental situations with a particular focus on technological innovations and eco-friendly solutions deployed in economically challenged communities.
孔雀創新公司總部設在俄亥俄州克利夫蘭，是一傢俱有社會意識的創新公司，致力於改善人們和地球的健康和福祉。孔雀石通過兩家全資運營的子公司部署這一雙重的、相互關聯的戰略。Graphium Biosciences是我們的運營子公司，致力於改善人們的健康和健康，該公司致力於推進我們利用我們專有的酶生物處理技術創造的100多種新型大麻苷化合物的廣泛產品組合，以開發針對慢性和衰弱疾病的安全有效的新療法，最初的重點是炎症性腸道疾病。Daedalus Ecosciences是我們致力於改善地球健康和福祉的運營部門，致力於識別、投資和重新定位具有挑戰性的環境狀況，特別關注在經濟困難社區部署的技術創新和生態友好型解決方案。
Notice Regarding Forward-Looking Statements
關於前瞻性陳述的通知
This press release contains "forward-looking statements" as that term is defined in Section 27(a) of the Securities Act of 1933, as amended and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Although we believe that these statements are based on reasonable assumptions, they are subject to numerous factors that could cause actual outcomes and results to be materially different from those indicated in such statements. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies, timing of clinical trials and product development, business strategy and new lines of business. These forward-looking statements are made as of the date of this press release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
本新聞稿包含“前瞻性陳述”，該術語在修訂後的1933年“證券法”第27(A)節和修訂後的1934年“證券交易法”第21(E)節中有定義。本新聞稿中非純粹歷史性的陳述是前瞻性陳述，包括任何有關對未來的信念、計劃、期望或意圖的陳述。儘管我們認為這些陳述是基於合理的假設，但它們受到許多因素的影響，這些因素可能導致實際結果和結果與此類陳述中顯示的結果大不相同。這些因素包括與新項目和開發階段公司相關的固有不確定性、臨牀試驗和產品開發的時間安排、業務戰略和新業務線。這些前瞻性陳述是截至本新聞稿發佈之日作出的，我們沒有義務更新前瞻性陳述，也沒有義務更新實際結果可能與前瞻性陳述中預測的結果不同的原因。儘管我們相信本新聞稿中包含的任何信念、計劃、預期和意圖都是合理的，但不能保證任何此類信念、計劃、預期或意圖將被證明是準確的。投資者應查閲此處列出的所有信息，還應參考我們最近一個會計年度的Form 10-K年度報告、Form 10-Q季度報告以及不定期提交給證券交易委員會的其他定期報告中概述的風險因素披露。
Malachite Innovations, Inc.
孔雀石創新公司
Investor Relations
投資者關係
P: +1 (216) 304-6556
P: +1 (216) 304-6556
E: ir@malachiteinnovations.com
電子郵箱：ir@malachiteInnovation ations.com
W: www.malachiteinnovations.com
W：www.malachiteInnovations.com
(END) Dow Jones Newswires
(完)道瓊通訊社
October 12, 2021 09:06 ET (13:06 GMT)
2021年10月12日東部時間09：06(格林尼治標準時間13：06)